Search Weight Loss Topics:

Page 11234..1020..»

Jan 10

The Week Unwrapped podcast: Testosterone, vegans and locusts – The Week UK

Olly Mann and The Week delve behind the headlines and debate what really matters from the past seven days.

In this weeks episode, we discuss:

Testosterone levels have been in decline for some time, and a long-term study published this week in the Journal of Sexual Medicine reveals the extent of the phenomenon: men aged between 15 and 39 now have 25% less testosterone than men of the same age in 1999 - a huge drop in just 20 years. Many theories have been put forward, including diet, lifestyle, underwear trends and even social attitudes towards masculinity. But why testosterone levels are dropping - and what the end result might be - remains a mystery.

An employment tribunal has ruled that ethical veganism is a philosophical belief akin to a religion that is protected by law against discrimination. But could the verdict come back to bite the growing movement? And which other beliefs are or should be safeguarded by our courts?

East Africa is in the grip of the most severe swarms of locusts in over 70 years, threatening food supply to millions across Somalia, Kenya and Ethiopia. With climate change fuelling their breeding and governments asleep at the wheel - are we all doomed to face more plagues in the future?

You can subscribe to The Week Unwrapped on theGlobal Player,Apple podcasts,SoundCloudor wherever you get your podcasts. It is produced by Sarah Myles and the music is by Tom Mawby.

Excerpt from:
The Week Unwrapped podcast: Testosterone, vegans and locusts - The Week UK

Jan 10

First-Ever Genomic Study of Puberty Yields Insights into Development, Cancer, and Infertility – Newswise


Available for logged-in reporters only

Newswise SALT LAKE CITY In the first-ever genome-scale analysis of the puberty process in humans, researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) outline distinct and critical changes to stem cells in males during adolescence. They further outline how testosterone, and the cells that produce testosterone, impact stem cells in male reproductive organs. The researchers believe this study adds dramatically to a foundation of knowledge that may yield insights into critical areas of human health, including infertility and cellular changes that lead to cancer and other diseases.

The study, published today in the journal Cell Stem Cell, was led by Bradley Cairns, PhD, cancer researcher at HCI and professor and chair of oncological sciences at the U of U, in collaboration with colleagues Jingtao Guo, PhD, a postdoctoral fellow in the Cairns lab at HCI, James Hotaling, MD, associate professor of surgery at the U of U, and Anne Goriely, PhD, associate professor of human genetics at the University of Oxford.

Puberty spurs numerous developmental changes in humans and other mammals. Hallmarks of puberty include physical characteristics easily visible to the naked eye, like rapid growth. These physical and hormonal changes signal the process of a maturing body preparing for reproductive years.

In the testis, the male reproductive organ that makes and stores sperm and produces testosterone, puberty introduces monumental changes at a cellular and physiological level. Thanks to new genomic technologies, researchers are able to examine the expression of thousands of genes in each individual cell in an entire organ, providing unprecedented insights into cellular behavior during puberty.

Several types of cells within the testis regulate reproductive health. Like the human body that changes along the path from infancy to adulthood, these cells undergo major changes as the body matures. These cells include spermatogonial stem cells that ultimately generate sperm production, and niche cells that help form parts of the testis, such as the seminiferous tubule, a tube-like structure within which sperm is formed. In this study, researchers characterized how, just prior to puberty, spermatogonial stem cells first expand significantly in number. These stem cells progress toward meiosis, a special type of cell division that splits the number of chromosomes from the parent cell in half, and also separates the male X and Y sex chromosomes to create cells that, after fertilization of eggs and considerable subsequent development, will ultimately result in either male (Y-containing) or female (X-containing) children. Late in puberty, these stem cells commit to creating mature sperm, which includes a tail piece for motility. The researchers showed how two of the cells that form the stem cell niche and chaperone this processthe myoid cells and Leydig cellsderive from a common precursor, and mature during early puberty.

A major novel insight of this study was the first-ever genomic analysis of the testis of adult transfemales (individuals assigned male at birth, but who self-identify as female). For these individuals, gender confirmation surgery is preceded by hormone therapy that induces long-term testosterone suppression, enabling the examination of testis lacking testosterone. By using samples donated after surgery, researchers uncovered critical insights into the role of testosterone in maintaining testis development. Genomic analysis of the cells from the testis of transfemales showed that stem cells and other cells revert to earlier states of development when compared to samples from male adolescents. Thus, Cairns and his colleagues identified that testosterone is critical to maintaining the mature state of the testis: if testosterone is no longer present, the testis reverts to an earlier developmental state.

The major changes that occur in humans during puberty give rise to numerous functions in normal development, like reproductive health and fertility. But, when these processes go awry, confounding challenges can result. Infertility is a relatively common health issue. About 50 percent of the time, the underlying cause is attributed to the male reproductive functions, which often include errors that occur during puberty. The team hopes these insights into how cells develop will help yield insights into what happens when developmental issues during puberty cause changes that result in infertility.

The study also informs understanding of cancer and other diseases that arise due to errors in cellular processes. The majority of the time, testicular cancers arise when stem cells in the testis are misregulated, said Cairns. We want to understand how these changes can cause testicular tumors; however, we need to know what should normally happen before we can identify ways to prevent or more effectively treat these cancers.

In juveniles, cancers and reproductive health intersect via a medical process called oncofertility; that is, the study of how to retain fertility in adolescent and young adult cancer patients whose reproductive health and fertility may be impacted by their cancer, or as a result of side effects of cancer treatment. Some chemotherapies can result in young men with cancer not being able to have childrenthe chemotherapy can cause changes to their stem cells, said Cairns. My hope and expectation is that our research will provide a foundation for creating options to support the reproductive health of young men affected by cancer through a better understanding of how these stem cells survive, are supported, and develop.

This research was supported by the National Cancer Institute grant P30 CA042014, the Howard Hughes Medical Institute, and Huntsman Cancer Foundation.


About Huntsman Cancer Institute:

Huntsman Cancer Institute(HCI) at theUniversity of Utahis the official cancer center of Utah. The cancer campus includes a state-of-the-art cancer specialty hospital as well as two buildings dedicated to cancer research. HCI treats patients with all forms of cancer and is recognized among the best performing cancer hospitals in the country by U.S. News and World Report. As the onlyNational Cancer Institute (NCI)-Designated Comprehensive Cancer Centerin the Mountain West, HCI serves the largest geographic region in the country, drawing patients from Utah, Nevada, Idaho, Wyoming, and Montana. More genes for inherited cancers have been discovered at HCI than at any other cancer center in the world, including genes responsible for hereditary breast, ovarian, colon, head, and neck cancers, along with melanoma. HCI manages theUtah Population Database, the largest genetic database in the world, with information on more than 11 million people linked to genealogies, health records, and vital statistics. HCI was founded byJon M. and Karen Huntsman.


Read the rest here:
First-Ever Genomic Study of Puberty Yields Insights into Development, Cancer, and Infertility - Newswise

Jan 10

In the know: Women in the news 1/6 – 1/10 – NBC News

How men can help women advance in the workplace

Businesses thrive when both genders are represented at the top of their companies, according to studies. But in order for women to achieve parity, men need to help women succeed in their careers, according to Forbes contributor and leadership professor Susan Madsen. She recommended that men fight gender discrimination in the workplace, recognize womens contributions in public and private settings, provide honest feedback and refine human resources processes and procedures.

States weigh measures to stop transgender athletes from competing in womens sports

In the past few weeks, at least five states have drafted legislation to regulate transgender participation in girl's and boys high school sports. Republican legislatures in New Hampshire, Washington, Georgia, Tennessee and Missouri have drafted bills primarily to bar transgendered students from playing on girls teams, citing physical unfairness. The bill in New Hampshire says that students can prove they are female by submitting proof of their female anatomy, testosterone levels and sex chromosomes.

Fired at 40, comeback at 54, how Ellen Latham built fitness giant Orange Theory

At age 40, Ellen Latham had a dream job as an exercise physiologist at a high-end spa. She appeared on TV frequently as a fitness expert. Then one day, she was fired. She was a single mom and had no idea what to do next. Fourteen years later, she became the founder of Orangetheory Fitness, a $1 billion franchise with 1,200 studios around the globe. Know Your Value interviewed Latham to learn about her drive, her comprehensive workout, and the new documentary Momentum Shift, which chronicles the rise of Orangetheory.

Get the knowyourvalue newsletter.

Raising my sensitive child was hell. Heres how we both survived her SPD, anxiety, and ADHD

There is hope for parents who are raising special needs children and having a difficult time. Thats the message from mother Jo Lomeo-Allen, who wrote a heartrending essay about raising her daughter who has ADHD, Sensory Processing Disorder, and Generalized Anxiety Disorder. Lomeo-Allen detailed her quest for diagnoses and treatment as her daughter threw hours-long tantrums over small things, such as a Cheerio dropping on the floor. Lomeo-Allen offered hope to parents and detailed her daughters road to stability.

Michelle Williams tells women at Golden Globes to vote in their self-interest, like men

Actress Michelle Williams didnt miss a chance to send a message during her Golden Globes acceptance speech Sunday. After accepting the award for Best Performance by an Actress in a Limited Series or Television Movie for her role in Fosse/Verdon, Williams encouraged women to vote in their own self-interest. So women, 18 to 118, when it is time to vote, please do so in your own self interest," Williams said. "It's what men have been doing for years which is why the world looks so much like them. Don't forget we are the largest voting body in this country. Let's make it look more like us."

How to stop stress-eating your way through the 2020 election

The upcoming election is a stress trigger for 56 percent of American adults, according to the American Psychological Association. Many of these adults overeat in order to cope with their stress. Clinical psychologists recommend that stress eaters take me time and limit their access to media. They suggest deep breathing, being social, and going for fruit instead of high-fat products.

All the celebrities who announced theyre expecting babies this year

Cameron Diaz, 47, announced the birth of her daughter Raddix on Friday. Other celebrities are following suit and announcing 2020 due dates, including actresses America Ferrera, Chloe Sevigny and Michelle Williams, according to Glamour. Others include U.S. Womens Soccer star Alex Morgan, actress Anne Hathaway, Laura Prepon from Orange is the New Black, and supermodel Petra Nmcov.

Black Britons know why Meghan Markle wants out

In the wake of Meghan Markle and Prince Harrys historic exit from the British royal family, Markle was called selfish and rogue by British press. However, writer Afua Hirsch argued that it was racism that pushed Markle and Prince Harry out of Buckingham Palace. Markle was the subject of extreme, unfair vitriol, which Hirsch believes is rooted in Britains history of class privilege, and the rising right-wing politics in the country.

Originally posted here:
In the know: Women in the news 1/6 - 1/10 - NBC News

Jan 10

Nuclear radiologists ‘outsmart’ prostate cancer with an apparently ineffective drug – Science Codex

When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewhat remote, rather idealistic genius sitting alone in their room or laboratory and somehow discovering the most amazing things without every having contact with the 'normal' world. But science is just as much a part of life as any other activity. So it's perhaps not all that surprising to learn that - just like in normal life - intuition can occasionally play a major role in scientific progress.

The importance of intuition was made very clear to Professor Samer Ezziddin and his team at the Department of Nuclear Medicine at Saarland University when they followed up on findings made during their medical research work into the treatment of patients with late-stage prostate cancer. The work centres around two receptors on the surface of the tumour. The first is known as prostate-specific membrane antigen (PSMA), a protein molecule that is very prevalent on the surface of prostate tumours. This surface receptor molecule acts as a gateway and provides a channel through which nuclear radiologists can smuggle radioactive substances into the tumour cells and thus destroy these malignant cells from the inside. The more PSMA molecules on the surface, the more radioactivity can be introduced into the cells without needing to increase the total dosage of radioactive substance being administered to the patient.

The second type of receptor is one that male sex hormones, such as testosterone, are able to dock onto. 'Prostate tumours need testosterone like a car needs petrol,' explains Professor Ezzidin. So one of the therapies used to treat prostate cancer involves blocking these receptor sites, which effectively stops the cancer from refuelling. 'One of the drugs used to block these receptors is enzalutamide and enzalutamide therapy is often very successful for a certain period of time, during which the tumour shrinks,' says Samer Ezzidin. 'But after a while - which might be several months, perhaps even two years if things go well - the drug stops working and the tumour starts to grow again.' Typically, the patient will then be taken off the expensive medication, as there would seem to be no reason to continue to administer it if it's no longer effective.

This is where the intuition of the Homburg research team comes to the fore. What may be of no use for one type of therapy (an ineffective drug) might turn out to be beneficial in another form of cancer therapy. 'We suspected, and later on we showed quite definitively, that the density of PSMA sites on the surface of the tumour cell increases when the adrogen receptor to which testosterone attaches is blocked,' says Ezzidin. The gut feeling within the research group, combined with the group's clinical observations, strongly suggested that this mechanism would still function in patients for whom the receptor-blocking drug (enzalutamide) was no longer itself therapeutically effective and was therefore no longer being prescribed.

The intuition of the medical research team proved to be spot on. 'We were able to prove that administering enzalutamide resulted in a significant increase in the PSMA density on the tumour surface, even though the drug was no longer effective in its original therapeutic sense and was no longer being prescribed for that purpose,' explains Samer Ezzidin. Despite the fact that only ten patients were involved the study, Professor Ezzidin believes that the results are compelling. 'After administering enzalutamide, we observed a significant increase in PSMA density on the tumour surface in all patients in the study. This allows us to introduce far more of the radioactive therapeutic agent into the tumour cells and thus irradiate them from the inside with irradiation paths that are down at the micrometre level,' says Ezzidin. As a result, PSMA radioligand therapy will be able to treat prostate tumours more efficiently and more selectively than has been possible in the past (see the following report for more details:

'These findings now need to be subjected to further study and corroborated in a future research project,' explains Professor Ezzidin. 'But we wanted to publish our results as quickly as possible, as our findings may be of help to lots of patients. That's why we decided to first issue this short communication. I expect that even this small-scale study will lead to a drastic change in the therapy management regimens used when treating patients with advanced prostate cancer,' says Samer Ezzidin. And it's very likely that Professor Ezzidin's intuition will once again turn out to be right on the mark.

See original here:
Nuclear radiologists 'outsmart' prostate cancer with an apparently ineffective drug - Science Codex

Jan 10

Testosterone Replacement Therapy Market Business Status, Industry Trends and Outlook 2020 to 2027 – Food & Beverage Herald

Testosterone Replacement Therapy Market 2019 by key players, regions, type, and application, forecast to 2027.The Report contains a forecast of 2019 and ending 2027 with a host of metrics like supply-demand ratio, Testosterone Replacement Therapy market frequency, dominant players of Testosterone Replacement Therapy market, driving factors, restraints, and challenges. The report also contains market revenue, sales, Testosterone Replacement Therapy production and manufacturing cost that could help you get a better view of the market. The report focuses on thekey global Testosterone Replacement Therapy manufacturers, to define and analyze the sales volume, value, market competition landscape, market share, SWOT analysis and development plans in future years.

The report includes substantial information pertaining to the produced goods, company profile, revenue graph, as well as other production patterns. The research study also presents details with respect to the market share that every company accounts for, as well as gross margins and price prototypes of the products.

Download FREE Testosterone Replacement Therapy PDF Brochure

Leading companies profiled andRegions Covered in the Testosterone Replacement Therapy Market include

The foremost points are labelled in detail which are covered in this Testosterone Replacement Therapy Market Report:

Market Overview: Scope & Product Overview, Classification of Testosterone Replacement Therapy by Product Category {Market Size (Sales), Market Share Comparison by Type (Product Category)}, Testosterone Replacement Therapy Market by Application/End Users {Sales (Volume) and Market Share Comparison by Application}, Market by Region (Market Size (Value) Comparison by Region, Status and Prospect.

Testosterone Replacement Therapy Market by Manufacturing Cost Analysis:Key Raw Materials Analysis, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials, Proportion of Manufacturing Cost Structure (Raw Materials, Labor Cost), Manufacturing Process Analysis.

Testosterone Replacement Therapy Players/Suppliers Profiles and Sales Data:Company, Company Basic Information, Manufacturing Base and Competitors, Product Category, Application and Specification with Sales, Revenue, Price and Gross Margin,Business Overview.

Click Here & Get DISCOUNT

Major Advantages for Testosterone Replacement Therapy Market:

The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Testosterone Replacement Therapy industry.

The current market is quantitatively reviewed from 2019 to 2027 to pinpoint the monetary competency of the global Testosterone Replacement Therapy market.

Well-organized description of the international Testosterone Replacement Therapy market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas.

The Testosterone Replacement Therapy market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis.

The report answers the following key aspects:

How is the Testosterone Replacement Therapy Market poised to show growth during the forecast period?

Who are the top players in the value stream of the Testosterone Replacement Therapy Market? What are the factors pushing their market growth?

Which segment will achieve the highest growth in the Testosterone Replacement Therapy Market?

Existing market trends.

Factors driving Testosterone Replacement Therapy market growth.

Market initiatives by the leading vendors.

Moreover, the report outlines characteristics and growth, SWOT analysis, segmentation, regional overview, competitive landscape, market share. In the conclusion part, the opinions of the industrial experts are incorporated as well as the growth factors of the Testosterone Replacement Therapy market are discussed in detail.

Request Sample Pages From the Reports:

Continue reading here:
Testosterone Replacement Therapy Market Business Status, Industry Trends and Outlook 2020 to 2027 - Food & Beverage Herald

Jan 9

AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant…

Paris, January 08, 2020, 7pm

FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy

Topline results expected to be available by end of 2020

AB Science SA (NYSE Euronext - FR0010557264 - AB) today announces that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to conduct its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy.

Study AB12003 is an international, multicenter, randomized, double blind, placebo-controlled, 2-parallel group, Phase 3 study in metastatic castrate resistant prostate cancer (mCRPC) eligible to chemotherapy. The study aims to compare the efficacy and safety of masitinib (6.0 mg/kg/day) in combination with docetaxel to placebo in combination with docetaxel. Docetaxel is combined with prednisone.

The study primary endpoint is progression free survival (PFS). A total of 468 patients are planned to be enrolled.

The target patient population consists of adult males who have progressed to develop metastatic castrate resistant prostate cancer (mCRPC) after castration treatment (i.e. reduction of available androgen/testosterone/DHT by chemical or surgical means) and are therefore eligible for chemotherapy.

An interim analysis was performed by the Independent Data Monitoring Committee (IDMC) in June 2018. Based on the rules set for the interim analysis, the recommendation from the IDMC was to continue the study in a pre-specified subgroup of patients that are identified by a biomarker. According to the statistical rule of the protocol at the interim analysis, this means that the probability of success of study AB12003 may exceed 80% in this pre-specified subgroup, assuming that the patients remaining to be enrolled behave similarly to those analyzed at the interim analysis. The subgroup of patients is expected to represent around two-thirds of the population.

AB Science expects the topline results from the trial to be available by end of 2020.

About castrate-resistant prostate cancer (CRPC)

Development of prostate cancer is often driven by male sex hormones called androgens, including testosterone. Castrate-resistant prostate cancer (CRPC) is defined by disease progression despite androgen depletion (hormone) therapy and may present as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases. Metastatic CRPC (mCRPC) occurs when the cancer spreads to other parts of the body.

Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per 100,000 men per year [1]. The estimated prevalence of people living with prostate cancer is 113 per 100,000 [2], with approximately 15% of the patients having metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy [3]. As such, population with metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy is around 75,000 in the EU and 50,000 in the USA.

Prostate cancer is also the second most common cause of cancer death in men, with the highest rates being in North America, Australia, and Northern and Central Europe. Although the overall 5-year survival rate for prostate cancer is very high, up to 20% of men who undergo state-of-the art treatment for prostate cancer will develop CRPC within 5 years, and at least 84% of these will have metastases at the time of CRPC diagnosis [1]. Practically all patients with metastatic disease become resistant to androgen-deprivation therapy. Median survival for those with mCRPC ranges from approximately 15 to 36 months in recent studies, and 5-year survival is only 28% [1].

References[1] Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017 May;35S:S1-S13. doi: 10.1016/j.urolonc.2017.01.020. [2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394424. [3] Scher 2015 PLoSONE - Symptomatic mCRPC that has not been treated with or not progressed on chemotherapy

About masitinibMasitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Companys lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, and inflammatory diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Sciences website:

Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorit des Marchs Financiers (AMF), including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB ScienceFinancial Communication & Media Relations

Read more:
AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant...

Jan 9

Testosterone Replacement Therapy Market Projections From 2020-2026 With Research Data on Consumption Analysis, Investment Cost, Profits Data and…

The global Testosterone Replacement Therapy market is broadly and deeply studied in the report with key focus on the competitive landscape, regional growth, market segmentation, and market dynamics. We have used latest primary and secondary research techniques for compiling this comprehensive research study. The report offers Porters Five Forces analysis, PESTLE analysis, competitive analysis, manufacturing cost analysis, revenue and production analysis, and various other types of analysis to provide a complete view of the global Testosterone Replacement Therapy market. Each segment of the global Testosterone Replacement Therapy market is carefully analyzed on the basis of market share, CAGR, and other vital factors. The global Testosterone Replacement Therapy market is also statistically presented with the help of Y-o-Y growth, CAGR, revenue, production, and other important calculations.

Get the Sample of this [emailprotected]

We can customize the report as per your requirements. Our analysts are experts in market research and analysis and have a healthy experience in report customization after having served tons of clients to date. The main objective behind preparing the research study is to inform you about future market challenges and opportunities. The report is one of the best resources you could use to secure a strong position in the global Testosterone Replacement Therapy market.

Market Segmentation:

Following are the segments covered by the report are:GelsInjectionsPatchesOtherBy Application:HospitalsClinicsOthersKey Players:The Key manufacturers that are operating in the global Testosterone Replacement Therapy market are:AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

Regional GrowthThe report offers in-depth analysis of key regional and country-level Testosterone Replacement Therapy markets, taking into account their market size, CAGR, market potential, future developments, and other significant parameters. The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Key Questions Answered What will be the size and CAGR of the global Testosterone Replacement Therapy market in 2025? Which product will gain the highest demand in the global Testosterone Replacement Therapy market? Which application could show the best growth in the global Testosterone Replacement Therapy market? What will be the nature of the competitive landscape in future? Which players will lead the global Testosterone Replacement Therapy market in the coming years? Which region will gain the largest share of the global Testosterone Replacement Therapy market?

Get Customized Report in your Inbox within 24 hours @

Table of Contents

Report Overview: It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Testosterone Replacement Therapy market segments by application, study objectives, and years considered.

Global Growth Trends: There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Testosterone Replacement Therapy Market Share by Manufacturer: Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type: It includes analysis of price, production value market share, and production market share by type.

Market Size by Application: This section includes Testosterone Replacement Therapy market consumption analysis by application.

Profiles of Manufacturers: Here, leading players of the global market are studied based on sales area, key products, gross margin, revenue, price, and production.

Testosterone Replacement Therapy Market Value Chain and Sales Channel Analysis: It includes customer, distributor, Testosterone Replacement Therapy market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more:
Testosterone Replacement Therapy Market Projections From 2020-2026 With Research Data on Consumption Analysis, Investment Cost, Profits Data and...

Jan 8

BLS Pharma Alleges Inovio’s Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender…

SANTA ANA, Calif.--(BUSINESS WIRE)-- BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free injection system that BLS Pharma was using to develop a drug-device combination (DDC) for testosterone replacement therapy.

Testosterone replacement therapy is a multi-billion-dollar market primarily used to treat male hypogonadism, a condition in which the body fails to produce enough testosterone. It is also a necessary treatment for transgender individuals transitioning and on lifetime hormone therapy from female to male.

Testosterone replacement therapy can make a significant difference for those in need of treatment. Our product would have allowed users to administer their treatments from the comfort of their own homes using a virtually painless needle-free system, said Mark Logomasini, President & CEO of BLS Pharma.

The shareholders of BLS Pharma previously developed the needleless injector technology, called Zetajet, and sold the intellectual property rights for it to Inovio and Genetronics, with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request. Under the agreement, BLS Pharma ordered 25,000 Zetajet units to prepare for its clinical trials on the DDC and was assured that the order was in process.

In September, BLS Pharma and Genetronics discussed the logistics of the syringe supply, and BLS Pharmas plan to offer the product for patients with hypogonadism and as a treatment for transgender males. The next business day, Inovio and Genetronics informed BLS Pharma they would not be supplying the syringes. This breach of contract eliminated BLS Pharmas ability to bring the DDC to market.

We are disappointed that we cannot offer this solution for male hypogonadism and to the transgender community, who have historically been marginalized by the medical and pharmaceutical community, stated Logomasini.

The testosterone treatment market is valued at 1.3 to 1.8 billion dollars annually. BLS Pharmas lost profits due to the breach of contract are estimated to be at least $72,900,000. All media inquiries should be directed to Jason Hartley of the Hartley LLP law firm at (619) 400-5822. For a copy of the complaint, email

View source version on

See the original post:
BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender...

Jan 8

Egg white and whey protein key to boosting male fertility, but slash ‘healthy’ fats and McDonald’s muffins –

Less surprisingly, it appears that a meal high in saturated fat, namely McDonald's sausage, cheese and egg muffins, along with hash browns, should also be shunned by men trying to become dads.

These are the findings highlighted in a new pilot study on overweight and obese men undertaken by academics at the University of South Australia and Flinders University.

They claim their findings present a direct link between diet and testosterone showing that what men eat could affect their fundamental male sex hormone.

They also believe their study is the first to identify that a diet high in any type of fat including healthy mono-saturated fats such as olive oil negatively impacts testosterone production over as little as five hours, yet one supplemented with egg whites, and to a lesser extent whey protein, can positively affect serum testosterone.

Globally, infertility affects15 per cent of couples, with theWorld Health Organizationestimating that up to 25 per cent of couples in developing countries are affected. While the causes are many and varied, 20-30 per cent of the problems are attributed to male factors alone.

Lead researcher, Dr Karma Pearce, says the preliminary findings present controversial insights over the link between testosterone and healthy monounsaturated fat, which is popularly considered to be a component of a healthy diet, including the Mediterranean dietary pattern.

The paper states: Many previous studies have shown a consistent 2030 per cent reduction in testosterone levels following a mixed meal. However, for the first time, this interventional study has clearly shown that the nature of macronutrient intake significantly impacts on testosterone production. The first key finding of this study is that fat, in both PUFA and MUFA forms, or a mixed meal of PUFA and CHO significantly reduced serum testosterone production to a similar degree over a 5 hour period.

Dr Pearce added there was an assumption that good fats and bad fats perform as theyre described.

However,whats surprising, is that it wasnt the type of fat that mattered at all, as an equal amount of the good and bad fats significantly supressed testosterone production."

In this study we also found that consumingalbumen the protein in egg whites increased testosterone levels, and did so by four-fold relative to fasting, while albumin, combined with the bad saturated fat somewhat ameliorated the effect of the bad fats on testosterone levels, providing another diet-based influencer of testosterone levels, Dr Pearce added.

Indeed, the paper reveals that a mixed meal of egg albumin and PUFA, compared to PUFA consumed alone, was able to blunt the postprandial drop in testosterone by 65 per cent, with the largest differences observed within the first, fourth, and fifth hour.

In all, the study tested eight diet protocols (meals comprising polyunsaturated fat from soyabean; monounsaturated fat from olive oil; refined carbohydrate (orange juice); whey; egg white; and mixed meals of polyunsaturated fat and refined carbohydrate; polyunsaturated fat and egg white; refined carbohydrate (orange juice and egg white) with four blood tests/hormone analyses taken before eating and at every hour afterwards for five hours.

While the researchers acknowledge they have tested individual nutrients and the effects may be different in the context of whole food dietary patterns, their earlier work has shown that Western diets typified by fast food dietary pattern produced a 25 per cent decrease in serum testosterone within an hour of eating, with levels remaining suppressed below fasting baseline for up to fourhours.

We have previously shown that a standard high-fat McDonalds meal of two English muffins (sausage, egg, and cheese) and two hash browns, containing approximately 50g of total fat, also decreased serum testosterone production over a 5 hour period by 9.8 2.4 nmol/L, the paper states.

Dr Pearce says the study is one step in a series of work needed to support and enhance fertility.

While the study only analyses the impact of various dietary macronutrients on testosterone production, not sperm quality, the researchers believe the study results suggest at least the potential for diet to negatively impact on sperm production and fertility.

Its important to note that its still early days and more research needs to be done, particularly at looking at the effect of these nutrients in the context of whole food dietary patterns over the longer-term, Dr Pearce added

Source: Nutrients

"The Effect of Macronutrients on Reproductive Hormones in Overweight and Obese Men: A Pilot Study"

Authors: Karma L Pearce, et al

Original post:
Egg white and whey protein key to boosting male fertility, but slash 'healthy' fats and McDonald's muffins -

Jan 8

Testosterone Replacement Therapy Market: Industry Growth Prospects & Trends Analysis by 2027 – Food & Beverage Herald

Testosterone Replacement Therapy Market report presents the worldwide market size (Value, Production and Consumption), splits the breakdown (data status 2014-2019 and 5 Forces forecast 2020 to 2027), by manufacturers, region, type and application. This Testosterone Replacement Therapy market report profiles major topmost manufactures operating ( AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals) in terms of analyse various attributes such asProduction, Consumption, Revenue, Gross Margin, Cost, Gross, Market Share, CAGR, and Market Influencing Factors of the Testosterone Replacement Therapy industry in USA, EU, China, India, Japan and other regions Besides, the report also covers Testosterone Replacement Therapy market segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

GetFREE Sample PDF (including full TOC, Tables and Figures)of Testosterone Replacement TherapyMarket @

Research Methodology

WordWide Market Reports follows a comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

Primary Research (Trade Surveys and Experts Interviews)

Desk Research

Proprietor Data Analytics Model

In addition to this, WordWide Market Reports has access to a wide range of the regional andglobal reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the360 Degree Perspective i.e. from theSupply Side andDemand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, aTop-Down approach andBottom-Up approach is followed to arrive at ultimate research findings.

Key Target Audience of Testosterone Replacement Therapy Market: Manufacturers of Testosterone Replacement Therapy, Raw Material Suppliers, Market Research and Consulting Firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Testosterone Replacement Therapy.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Experts:

There Are 11 Chapters To Deeply Display The Testosterone Replacement Therapy Market.

Chapter 1, is definition and segment of Testosterone Replacement Therapy; Chapter 2, is executive summary of Testosterone Replacement Therapy Market; Chapter 3, to explain the industry chain of Testosterone Replacement Therapy; Chapter 4, to show info and data comparison of Testosterone Replacement Therapy Players; Chapter 5, to show comparison of types; Chapter 6, to show comparison of applications; Chapter 7, to show comparison of regions and courtiers(or sub-regions); Chapter 8, to show competition and trade situation of Testosterone Replacement Therapy Market; Chapter 9, to forecast Testosterone Replacement Therapy market in the next years; Chapter 10, to show investment of Testosterone Replacement Therapy Market;

Key Questions Answered in the Testosterone Replacement Therapy Market Report:

What are the most recentAdvanced Technologies Adopted by Testosterone Replacement Therapy?

How are the recent trends affecting growth in the global Testosterone Replacement Therapy market?

What are theKey Strategies Used By Players And Service Providers that are expected to impact the growth of the Testosterone Replacement Therapy market?

What are theResources Available In Respective Regions that attract leading players in the Testosterone Replacement Therapy market?

What was theHistorical Value and what will be the forecast value of the Testosterone Replacement Therapy market?

Read the original here:
Testosterone Replacement Therapy Market: Industry Growth Prospects & Trends Analysis by 2027 - Food & Beverage Herald

Page 11234..1020..»